Posted: November 30, 2009 at 11:19 am
By Chuck
It sure sounds like Boehringer Ingelheim Vetmedica did very well in the cattle market with their acquisition of a portion of Ft. Dodge Animal Health. To tell us about is Tim Bettington, Director Livestock Marketing. I spoke with him at their recent media day in St. Joseph, MO. He says that although BIVI has been a long standing player in the cattle business it has only been in certain segments like the stocker and feedlot sector. But now he says they have great opportunities in the cow/calf and dairy sectors.
According to Tim, the stand out products will be Cydectin, Today and Tomorrow Mastitis Tubes and newer vaccines like Triangle. He says that although there is an integration of staff, customers will see the same look and feel of the products and deal with the same representatives they were dealing with.
You can listen to my interview with Tim below.
Podcast: Play in new window
| Download
Posted: November 21, 2009 at 7:13 pm
By Chuck
With the acquisition of Ft. Dodge Animal Health products and facilities, Boehringer Ingelheim Vetmedica has really expanded their business in the dairy industry. The head of the U.S. cattle business is Colin Meyers. He spoke at the media event I attended in St. Joseph, MO.
Colin says the main thing the acquisition of Ft. Dodge Animal Health means to the company is that they now have a much broader range of products to offer. For the dairy sector they now offer Pyramid, Triangle, Presponse, Today and Tomorrow mastitis therapy, Cydectin and more.
Colin says they’ll have a larger sales and veterinarian force to reach out to customers and a bigger distribution network. They’ve spent the last three weeks bringing in new staff, distributors and others to help enable a smooth transition for customers.
You can listen to my interview with Colin below.
Boehringer Ingelheim Vetmedica Media Day Photo Album
Podcast: Play in new window
| Download
Posted: November 21, 2009 at 4:49 pm
By Chuck
Now that Boehringer Ingelheim Vetmedica has taken over a significant portion of Ft. Dodge Animal Health you may be wondering what it means to the company and dairy producer customers. To help us find out, BIVI brought a group of media representatives into St. Joseph, MO to hear the story.
I spoke with BIVI President, George Heidgerken (pictured on left), about changes in the company after the acquisition. He says the purchase is a big deal for BIVI here in the United States and globally since it essentially doubles their business including their ability to innovate in the future. While merging the two company cultures he says they will maintain the BI vision and mission and how they achieve them.
George says they can take the best of both companies, put them together and get excited about what they can achieve. They’re calling it the “new BIVI.” He says that full integration may take a couple years although they hope to achieve that sooner. The products they’ve acquired fit in perfectly with their existing portfolio and expand their cattle, dairy and pet business. The vision for the future of the company he says, is “value through innovation.”
You can listen to my interview with George below.
Here’s a group of photos from the media event last Thursday Boehringer Ingelheim Vetmedica Media Day Photo Album
Podcast: Play in new window
| Download
Posted: October 27, 2009 at 10:24 am
By Cindy Zimmerman
Boehringer Ingelheim Vetmedica Inc. (BIVI) has closed a deal with Pfizer to acquire a significant portion of the Fort Dodge Animal Health business. The acquisition, which includes products in the U.S., Australia, Canada and South Africa, as well as two manufacturing and research facilities located in Fort Dodge, Iowa, significantly increases the size of Boehringer Ingelheim’s companion animal and cattle portfolios and strengthens the company’s position as a leading vaccine supplier.
“We’ll be expanding our business significantly, in fact, doubling our sales in the United States,” said BIVI president George Heidgerken. “The product assets we’ve acquired from Fort Dodge are a broad range of strong brands in the cattle vaccine business. This is part of our long term strategy to improve our product offerings and our capabilities for the U.S. cattle producers and the U.S. cattle market.”
The cattle vaccines included in the acquisition include the Triangle®, Pyramid®, and Presponse® vaccine lines. Pharmaceutical products being acquired include Cydectin® (moxidectin) for cattle and sheep as well as Polyflex® (ampicillin sodium). The dairy portfolio includes the key brands Today® and Tomorrow®.
Listen to or download an interview with George Heidgerken here:
Podcast: Play in new window
| Download
